Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-31
2009-12-08
Marschel, Ardin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S345000, C514S340000, C514S344000, C514S895000, C546S290000, C546S296000, C546S300000, C546S302000
Reexamination Certificate
active
07629365
ABSTRACT:
3-Chloro-6-(hydroxymethyl)-2-methyl-5-[4-({4-[(trifluoromethyl)oxy]phenyl}oxy)phenyl]-4(1H)-pyridinone, having the following formula:is described along with its pharmaceutically acceptable salts, processes for its preparation, pharmaceutical formulations thereof and its uses in treatment of certain parasitic infections such as malaria.
REFERENCES:
patent: 5403934 (1995-04-01), Batchelor et al.
patent: 0447164 (1991-09-01), None
patent: WO-9113873 (1991-09-01), None
Nitta et al, Mo(CO)n induced N-O bond cleavage of isoxazoles a convenient route to pyridin-4(1H) ones, Heterocycles, vol. 38, No. 4 1994.
Patani et al , bioisosterism: A rational Approach in drug design, Chemical reviews, 1996, vol. 96, pp. 3147-3176.
Bueno Calderon Jose Maria
Chicharro Gonzalo Jesus
Manzano Chinchon M Pilar
Glaxo Group Limited
Lemanowicz John
Marschel Ardin
Rao Savitha
Willis Reid S.
LandOfFree
Heterocyclic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Heterocyclic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4106885